Neonatal Respiratory Distress Syndrome Treatment Market Ongoing Research And Development Activities Are Expected To Propel Growth Of The Global Market | Chiesi Farmaceutici S.P.A, JW pharmaceuticals

When a newborn is born, they are likely to be in danger of developing Neonatal respiratory distress syndrome (RDS). This life-threatening condition is caused by a lack of pulmonary surfactant. The risk of developing RDS increases with the degree of prematurity. Signs of this condition include grunting respirations, the use of accessory muscles, and nasal flaring. Treatment for this disease involves a combination of supportive care and surfactant therapy. The birth process is an arduous process with extensive physiologic changes.

Get Free Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4074

Neonatal Respiratory Distress Syndrome Treatment Market – Drivers

According to the U.S National Library of Medicine, in 2015, neonatal respiratory distress syndrome was found in 6 to 7% neonates in the U.S. Such rise in prevalence of Neonatal respiratory distress syndrome is driving market growth. Thus, there is potential opportunity for pharmaceutical companies to expand their presence in the neonatal respiratory distress syndrome treatment market. Also, pharmaceutical companies are adopting various growth strategies such as mergers and acquisitions to achieve growth and make profits in neonatal respiratory distress syndrome treatment market. For instance, in 2017, Aerogan Pharmaceuticals and Lyomark Pharmaceuticals merged with the aim of developing AP-002, a clinically superior treatment for neonatal respiratory distress syndrome. These factors are expected to drive the neonatal respiratory distress syndrome treatment market growth.

Neonatal Respiratory Distress Syndrome Treatment Market – Impact of COVID-19

Patients with respiratory distress syndrome are at severe risk of COVID-19. Whereas, in case neonates with respiratory distress syndrome are at minimal risk due to COVID-19 compared to adults owing to less chance of community transmission. However, there is a chance of getting infected in the womb or due to close contact with an infected adult. On the other hand, surfactant therapy and mechanical ventilation are some of the efficient treatments for neonatal distress syndrome in COVID-19 patients. As a result, the global neonatal respiratory distress syndrome treatment market is expecting to experience moderate growth during the pandemic.

Neonatal Respiratory Distress Syndrome Treatment Market- Restraints.

Risk associated with treatment as oxygen therapy and mechanical ventilation therapy is associated with difficulty in breathing and coughing caused by breathing tube is hindering market growth. In surfactant therapy, there is risk of bradycardia, hypoxemia during instillation in neonates.

Additionally, the cost of neonatal ventilation is high and may be unaffordable for many patients in under developed countries such as India. These factors are projected to hamper global neonatal respiratory distress syndrome treatment market growth.

Neonatal Respiratory Distress Syndrome Treatment Market-Regional Analysis.

Among regions, the global respiratory distress syndrome treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, U.S. holds a dominant position in the neonatal respiratory distress syndrome treatment market owing to increasing prevalence of neonatal respiratory distress syndrome in the country. According to the U.S National Library of Medicine, in 2014 to 2016 around 12% of the babies born in the U.S. Are suffering from neonatal respiratory distress syndrome. Pharmaceutical companies are focusing on mergers and acquisitions strategies owing to high growth opportunities in the neonatal distress syndrome market. For instance, in 2018, Windtree Therapeutics and CVie Therapeutics announced their merger which was named Windtree Therapeutics. Through this merger, under the name of Windtree Therapeutics, will be fully integrated and diversified acute care company with four mid late clinical stage products including Aerosurf.

Moreover, the market in Europe is projected to experience significant growth owing to the growing awareness regarding neonatal respiratory distress syndrome. Increasing research and development activities by pharma companies is favoring growth of the neonatal respiratory distress syndrome market. For instance, in 2017, Chiesi Farmaceutici S.p.A sponsored Saint Mary hospital research unit to carry out the ‘CURONEB’ study which involved investigation of safety, tolerability and efficiency of inhaled nebulized Curosurf used in the treatment of neonatal respiratory distress syndrome.

Furthermore, Asia Pacific is projected to provide significant growth, as well as technological advancement in medical devices which are augmenting the growth of the market in this region. For instance, in 2019, InnAccel Technologies Pvt Ltd. (India) launched SAANS: portable neonatal CPAP device for infants with respiratory distress syndrome. SAANS is the only CPAP device with multiple power options, including a patented manual mode.

Neonatal Respiratory Distress Syndrome Treatment Market- Competitive Landscape.

Chiesi Farmaceutici S.P.A, JW pharmaceuticals, Aragon Pharmaceuticals Inc, Lyomark Pharma GmbH, Takeda Pharmaceutical Company Limited, Menzies Institute for Medical Research, InnAccel Technologies Pvt Ltd, and Windtree Therapeutics, Inc.

Key development-

1. In May 2020, J.K Lon Government Children Hospital (India) launched less invasive surfactant administration treatment (LISA) for neonatal respiratory distress syndrome.
2. In February 2020, Windtree Therapeutics initiated a study on efficacy and safety of Lucinactant for inhalation in preterm neonates 26 -32 weeks of age suffering from neonatal respiratory distress syndrome.
3. In 2018, the Catholic University of Sacred Heart completed clinical trial of a new technique called IN-REC-SUR-E in preterm neonates with respiratory distress syndrome. The treatment involves the Proactant Alfa drug, high frequency oscillating ventilator and neonatal continuous positive air pressure nasal cap.

Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4074

Neonatal Respiratory Distress Syndrome Treatment Market- Taxonomy.

• By Treatment Type-
  • Continuous Positive Airway Pressure Therapy
  • Surfactant Therapy
  • Neonatal Ventilation
• By End User-
  • Hospital
  • Clinics
  • Ambulatory Care Centres
• By Region-
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Reasons To buy The Neonatal Respiratory Distress Syndrome Treatment Market Report:

➛ In-depth analysis of the market on the global and regional levels.

➛ Major changes in market dynamics and competitive landscape.

➛ Segmentation on the basis of type, application, geography, and others.

➛ Historical and future market research in terms of size, share growth, volume, and sales.

➛ Major changes and assessment in market dynamics and developments.

➛ Emerging key segments and regions

➛ Key business strategies by major market players and their key methods.

Buy This Complete Business Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4074

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Neonatal Respiratory Distress Syndrome Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Neonatal Respiratory Distress Syndrome Treatment Industry Impact

Chapter 2 Global Neonatal Respiratory Distress Syndrome Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Neonatal Respiratory Distress Syndrome Treatment (Volume and Value) by Type
2.3 Global Neonatal Respiratory Distress Syndrome Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Neonatal Respiratory Distress Syndrome Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 6 East Asia Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 7 Europe Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 8 South Asia Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 9 Southeast Asia Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 10 Middle East Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 11 Africa Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 12 Oceania Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 13 South America Neonatal Respiratory Distress Syndrome Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Neonatal Respiratory Distress Syndrome Treatment Business
Chapter 15 Global Neonatal Respiratory Distress Syndrome Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology